Cboe: Proprietary index options volume and prediction markets launch price in a perpetual slow-growth exchange story

Stevie AI on Cboe Global Markets Inc (CBOE-USA | cboeglobalma)

4/18/2026

Summary

Cboe Global Markets operates the dominant global franchise in proprietary index options — SPX, VIX, and Russell 2000 — a product set that no competitor can replicate without licensing agreements Cboe controls. This is not a generalist exchange competing on price; it is a structurally advantaged derivatives venue where volume is driven by product innovation (zero-DTE options now representing 61% of SPX volume with 66% YoY growth) and secular demand from institutional and retail hedgers who have no substitute venue. The market continues to price Cboe as a mature, low-growth exchange business. That framing misses three compounding drivers: accelerating zero-DTE adoption, a Global Trading Hours extension running at +34% YoY, and a prediction markets launch in Q2 2026 that would create an entirely new securities-based event contract category — with Cboe as the only regulated venue. The financial record supports the re-rating case. Revenue grew from $4.1B in FY2024 to $4.7B in FY2025, a 15% step-up that reflected derivatives volume acceleration and DataVantage organic growth. Net income expanded from $0.8B to $1.1B, and EPS surged 44% from $7.21 to $10.42 — a pace that a mid-twenties P/E multiple does not adequately capture if the trajectory continues. Free cash flow generation is strong enough to sustain $300–400M in annual buybacks and approximately 10% annual dividend per share growth simultaneously, with net cash on the balance sheet building from $1.6B in FY2026 to $4.9B by FY2029. The combination of volume-driven revenue growth, operating leverage on a guided $864–879M adjusted OpEx base, and aggressive capital return creates a multi-year compounding total return profile that the current price undervalues. Applying a 25x forward P/E to FY2026 EPS of $12.18 yields a price target of $304.50, modest upside from the current $299.94 but with targets stepping meaningfully higher as the EPS path unfolds: $344 in 2027, $382 in 2028, and $425 in 2029. The 25x multiple is appropriate for a high-quality financial infrastructure business with proprietary product IP, mid-to-high single-digit revenue growth, improving margins, and a net cash balance sheet. It sits at a modest premium to the broader exchange sector but a discount to pure data and index businesses that trade at 30x+, reflecting residual volume cyclicality risk. As prediction markets revenue becomes visible and DataVantage organic growth accelerates, a re-rating toward 27–28x is achievable, adding a further 8–12% to the 2027–2028 price targets.

Thesis

1. **Zero-DTE and Global Trading Hours: Volume Growth That Is Structural, Not Cyclical** The conventional view of exchange volume is that it is cyclical — tied to market volatility, risk appetite, and macro conditions. Cboe's zero-DTE SPX options business is disrupting that narrative. Zero-day-to-expiry options now account for 61% of all SPX volume, having grown 66% year-over-year, and the driver is not a single volatility episode but a structural shift in how institutions and sophisticated retail participants manage intraday risk and express tactical views. The product did not exist at scale three years ago. Cboe created the category and owns the underlying index — the S&P 500 options contract is exchange-licensed and cannot be offered by a competitor without Cboe's consent. Global Trading Hours (GTH) extend Cboe's addressable trading day for SPX and VIX options into European and Asian sessions. GTH volume is growing at +34% YoY, driven by international broker adoption and the practical reality that global portfolio managers need to hedge dollar-denominated equity risk outside U.S. hours. The combination of zero-DTE intraday products and GTH extended-session products means Cboe is simultaneously deepening U.S. penetration and expanding internationally without building new exchange infrastructure. This is pure operating leverage — incremental volume on a fixed-cost venue. Forecasts assume this momentum continues at a moderated but still-healthy pace, with proprietary derivatives driving the majority of net revenue CAGR of 5–8% through 2029. Even if zero-DTE growth decelerates to 20–30% from 66%, the absolute volume base is large enough to generate meaningful fee revenue growth. The structural case does not depend on peak volatility — it depends on continued adoption of a product set that has become the preferred hedging and speculation vehicle for an expanding universe of participants. 2. **DataVantage: Recurring Revenue Engine With International Expansion Optionality** DataVantage — Cboe's market data, index licensing, and risk analytics segment — is the segment the market most consistently undervalues because it is bundled into a derivatives and equities exchange story. Management has guided mid-to-high single-digit organic growth for FY2026, which is consistent with the segment's recent trajectory of international data distribution expansion and index licensing deals. Critically, 45% of new data sales are now coming from international distribution, a channel that was negligible three years ago. The economics of index licensing are particularly attractive. When Cboe's proprietary indices (S&P 500 options settlement index, VIX, Russell 2000) are used as the basis for ETFs, structured products, or OTC derivatives by third parties, Cboe earns a licensing fee with near-zero marginal cost. As passive investing continues to grow globally and international asset managers build more S&P-linked products, the index licensing revenue stream expands without requiring Cboe to do anything other than maintain its index methodology and settlement infrastructure — which it already does for its own listed products. DataVantage revenue is subscription and licensing-based, carrying higher margin and lower volatility than transaction fees. As its share of total revenue grows, the blended margin profile of the business improves and the earnings multiple should logically expand toward data-business comps (30x+) rather than transaction-exchange comps (20–22x). The current 25x blended multiple does not yet reflect this mix shift, which we expect to become more visible in the 2027–2029 period as DataVantage approaches $1.5B+ in annual revenue. 3. **Prediction Markets: A New Revenue Category With Regulatory Timing as the Swing Factor** Cboe's targeted Q2 2026 launch of securities-based prediction markets represents the highest-optionality item in the investment case. Prediction markets — event contracts on election outcomes, economic data releases, and sports events structured as securities rather than CFTC-regulated derivatives — would allow Cboe to capture transaction fee revenue from a category that has so far been dominated by unregulated offshore venues (Polymarket) or narrowly licensed domestic operators (Kalshi). The SEC regulatory environment under the current administration has been cited by management as constructively positioned for securities-based event contracts. If approved, Cboe would be the only major regulated U.S. securities exchange offering these products, giving it first-mover advantages in onboarding retail broker platform partners, institutional market makers, and liquidity providers. The incremental revenue contribution is expected from 2027 onward in forecasts, but the upside scenario — if retail participation in prediction markets via existing brokerage accounts proves as large as zero-DTE adoption — is not captured in the base case. Even conservatively, prediction markets provide Cboe with a narrative catalyst that could re-rate the stock ahead of revenue recognition. The Q2 2026 launch announcement alone — if accompanied by named broker-dealer partners and OCC clearing approval — would likely compress the discount at which Cboe trades relative to its intrinsic value as a financial infrastructure innovator. The risk is binary at the regulatory level, but the asymmetry is favorable: delay is the downside, not permanent impairment. 4. **Operating Leverage on a Guided Expense Base: Margin Expansion Is Arithmetic** Cboe has provided explicit FY2026 adjusted operating expense guidance of $864–879M, representing 3.3–5.1% growth on the prior year. Against a mid-single-digit revenue growth trajectory, this produces operating leverage that mechanically improves the efficiency ratio (adjusted OpEx as a percentage of net revenue). Forecasts project the efficiency ratio declining toward 19% by 2029 from a higher current level. This is not a heroic assumption. It requires only that management holds expense growth to the guided range — a task that is more credible following the strategic realignment actions already executed (Canada and Australia divestitures, FedEx closure). These moves reduced fixed cost obligations and headcount in lower-margin geographies, freeing capital allocation for higher-return organic investments (GTH infrastructure, prediction markets platform) at minimal incremental cost. The restructuring is largely complete; the margin benefit accrues from FY2026 onward. Net income is projected to grow from $1.1B in FY2025 to $1.7B by FY2029, and EPS from $10.42 to $17.01 over the same period — a 63% cumulative increase driven by both earnings growth and a materially shrinking share count from sustained $300–400M annual buybacks. At the current price of $299.94, investors are paying 28.8x trailing FY2025 EPS, but only 24.6x FY2026 EPS and 17.7x FY2029 EPS. The forward curve of earnings growth is not priced into a stock that trades as if growth will stall at current levels. 5. **Capital Return and Balance Sheet Quality: Shareholder Value Compounding Without Financial Risk** Cboe's balance sheet trajectory is unusual for a company growing earnings at this pace. Net cash is projected to build from $1.6B in FY2026 to $4.9B by FY2029 even after sustaining $300–400M in annual buybacks and approximately 10% annual DPS growth. Free cash flow grows from $1.6B in FY2026 to $2.1B by FY2029, providing substantial coverage for both capital return programs and any opportunistic M&A without requiring leverage. The dividend growth rate of approximately 10% per year is not a token gesture — it signals management's confidence in the earnings trajectory and provides a yield-support floor for the stock during periods of market volatility or volume softness. Combined with the buyback program reducing the share count by an estimated 1–2% annually, the total shareholder yield is approximately 3–4% per year at current prices, before any price appreciation. For a business with this earnings growth profile, that yield is additive rather than compensatory — Cboe is not paying a high dividend because growth is absent; it is paying a growing dividend because cash generation exceeds reinvestment needs. 6. **Valuation: The Market Is Pricing Exchange Cyclicality, Not Infrastructure Compounding** At $299.94, Cboe trades at 28.8x FY2025 EPS — a number that sounds full until examined in context. CME Group trades at approximately 24–26x with lower organic growth and no prediction markets optionality. Intercontinental Exchange trades at 22–24x with significant mortgage technology drag. MSCI, a pure index and data business that is the closest comparable to Cboe's DataVantage segment, trades at 35–40x. Cboe's blended business — approximately 60% transaction-based, 40% recurring data and licensing — deserves a valuation between pure transaction exchange and pure data business multiples. The 25x forward multiple applied here is deliberately conservative, reflecting volume cyclicality risk and regulatory uncertainty around prediction markets. It implies a FY2026 price target of $304.50, FY2027 of $344, FY2028 of $382, and FY2029 of $425 — a 42% total price return to the 2029 target, or approximately 9% annualized price appreciation plus the dividend. If prediction markets launch successfully and DataVantage's recurring revenue mix increases, the appropriate multiple is 27–28x, adding $35–50 to the 2027–2028 targets. The re-rating case is not dependent on a macro tailwind; it is dependent on Cboe executing on product launches and expense guidance that management has publicly committed to.

Risks

1. **Regulatory Risk on Prediction Markets Could Eliminate the Primary Re-Rating Catalyst** The Q2 2026 prediction markets launch is the highest-profile near-term catalyst in the investment case, and it is entirely dependent on SEC approval of securities-based event contracts and OCC readiness to clear them. The SEC has shown constructive signals, but regulatory timelines are notoriously difficult to predict and a change in commission composition, legal challenge from CFTC on jurisdictional grounds, or adverse interpretation of binary options classification could delay the launch by 12–24 months or prevent it entirely. A delayed launch would remove the 2027 incremental revenue contribution from forecasts and — more importantly — deflate the narrative premium that prediction markets adds to the investment case. The stock could de-rate 5–8% on a credible delay announcement even if the core derivatives and data business remains on track. 2. **Zero-DTE Volume Growth Deceleration or Structural Mean Reversion** Zero-DTE SPX options volume has grown 66% YoY and now represents 61% of total SPX volume. The base effect alone will make future percentage growth rates appear smaller, but the deeper risk is that adoption plateaus as the incremental universe of institutional and retail zero-DTE participants becomes saturated. Academic and regulatory research on zero-DTE risk — including potential contributions to intraday volatility — has attracted attention from the SEC and FINRA. If regulators impose position limits, margin increases, or suitability restrictions on zero-DTE products, volume could decline meaningfully from current levels. The forecasts model continued growth at a moderated pace; a reversion to flat or negative zero-DTE volume would reduce FY2026 EPS by an estimated $1.00–1.50, compressing the entry multiple justification. 3. **DataVantage Organic Growth Disappoints Relative to Mid-to-High Single-Digit Guidance** DataVantage is the highest-quality segment by revenue visibility, but mid-to-high single-digit organic growth is not guaranteed. The segment faces competition from Bloomberg, Refinitiv (LSEG), and FactSet in data distribution, and index licensing revenue is sensitive to the pace of ETF and structured product issuance globally. If international data distribution deals slow — due to a stronger dollar reducing international asset manager budgets, or competitive pricing pressure from European data vendors — DataVantage growth could come in at the low single-digit range. At 40% of revenue, a 3–4 percentage point DataVantage growth miss versus guidance would reduce total net revenue by approximately $75–100M annually, compressing EPS by $0.50–0.70 relative to forecasts. 4. **Market Volatility Normalization Reduces Derivatives Transaction Fee Revenue** Approximately 60% of Cboe's revenue remains transaction-fee-based, and while zero-DTE has reduced the single-day volatility spike dependency of that revenue, sustained low-volatility environments — where the VIX trades below 12 for extended periods — meaningfully reduce hedging demand and speculative volume. The VIX has averaged approximately 15–18 over the recent period; a reversion toward 10–12 (as seen in 2017) would reduce derivatives transaction revenue by an estimated 10–15%, potentially cutting FY2026 EPS to $10.50–11.00 versus the $12.18 base forecast. This is the most classical exchange sector risk and the primary reason a 25x rather than 28–30x multiple is applied. 5. **Expense Creep Beyond Guided Range Compresses Operating Leverage Thesis** Management has guided FY2026 adjusted OpEx at $864–879M (3.3–5.1% growth), and the operating leverage thesis depends on holding expense growth to this range through 2029. Risks to this include: technology investment overruns on the prediction markets platform and GTH infrastructure; severance and integration costs from completed divestitures that bleed into FY2026 reported figures; and wage inflation in the competitive financial technology talent market. If expenses grow at 7–8% annually rather than 3–5%, the efficiency ratio improvement stalls and FY2029 EPS is reduced by $1.00–1.50. The strategic realignment actions completed in FY2025 reduce this risk but do not eliminate it. 6. **Competitive Encroachment in Multi-List Options and FX Markets** While Cboe's proprietary index options business is structurally protected, approximately 35–40% of derivatives revenue comes from multi-list options and futures where Cboe competes with 20+ venues. In multi-list options, Cboe holds 22% market share but competes on maker-taker pricing against Nasdaq PHLX, MIAX, and others. Any structural shift in routing incentives — regulatory fee pilot programs, changes to the national market system, or aggressive pricing from well-capitalized competitors — could erode Cboe's multi-list share. Similarly, the Global FX business competes with institutional EBS (CME) and other electronic venues where switching costs are low and pricing pressure is chronic. A 1–2 percentage point market share loss in multi-list options would reduce net revenue by approximately $40–60M annually.

📈 Price Targets